期刊
CURRENT PHARMACEUTICAL DESIGN
卷 11, 期 1, 页码 3-10出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612053382368
关键词
probiotics; prebiotcs; synbiotics; enteric microflora; mucosal adherence; inflammatory bowel disease; pouchitis; colon cancer
There is considerable clinical interest in the utility of probiotic therapy - the feeding of (live) non-pathogenic bacteria, originally derived from the alimentary tract, for disease treatment or health promotion. The microflora of the gastrointestinal tract is essential for mucosal protection, for immune education and for metabolism of fecal residue. Physiological disturbances of these processes, when they occur, result from: i) alteration of a microbial ecosystem, originally conserved. by evolution; ii) reduced consumption of microorganisms; iii) invasion of pathogens; or iv) modern interventions, Recent data support the use of proven probiotic organisms in prevention and treatment of flora-related gastrointestinal disorders including inflammatory bowel disease, infectious and antibiotic related diarrheas, and post-resection disorders including pouchitis. Therapeutic activity of probiotic bacteria can be due to competition with pathogens for nutrients and mucosal adherence, production of antimicrobial substances, and modulation of mucosal immune functions. Although a promising treatment, controlled clinical trials are necessary to validate the benefit of probiotics
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据